1. Measuring health system performance

   • P.C. Smith

   Editorial 11 February 2014 Pages: 145 - 148

2. Budget impact model for determining the costs of introducing inhaled salmeterol/fluticasone propionate combination for the management of persistent asthma in France

   • B. Detournay
   • C. Pribil
   • M. Price

   Original papers 11 February 2014 Pages: 149 - 155

3. Disease progression in amyotrophic lateral sclerosis

   • M. Tavakoli

   Original papers 11 February 2014 Pages: 156 - 165

4. Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine

   • M. Herold
   • K. Hieke

   Original papers 11 February 2014 Pages: 166 - 172

5. A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia

   • K. Hansen
   • C. François
   • C. Lançon

   Original papers 11 February 2014 Pages: 173 - 179

6. Modelling the costs and effects of leflunomide in rheumatoid arthritis

   • G. Kobelt
   • P. Lindgren
   • A. Young

   Original papers 11 February 2014 Pages: 180 - 187

7. Medical savings accounts: a core feature of Singapore's health care system

   • W. von Eiff
   • T. Massoro
   • R. Ziegenbein

   Invited papers 11 February 2014 Pages: 188 - 195

8. Methodological guidelines for conducting economic evaluation of healthcare interventions in Hungary: a Hungarian proposal for methodology standards

   • Ágota Szende
   • Z. Mogyorósy
   • C Dözsa

   Invited papers 11 February 2014 Pages: 196 - 206

9. Restructuring of the healthcare system and the diffusion of telemedicine

   • M. Kerleau
   • N. Pelletier-Fleury

   Congress papers 11 February 2014 Pages: 207 - 214

10. Pricing and reimbursement of pharmaceuticals in Norway

    • A. Hågå
    • J. M. Sverre

    Pricing and Reimbursement Systems in Europe 11 February 2014 Pages: 215 - 220